您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (9): 24-29.doi: 10.6040/j.issn.1671-7554.0.2014.908

• 基础医学 • 上一篇    下一篇

CXCL16在阿霉素肾病小鼠中的表达及辛伐他汀对其的影响

王聪1, 孙书珍1, 甄军晖2, 李倩1, 许艺怀1   

  1. 1. 山东大学附属省立医院小儿肾脏风湿免疫科, 山东 济南 250021;
    2. 山东大学医学院病理学教研室, 山东 济南 250012
  • 收稿日期:2014-12-07 出版日期:2015-09-10 发布日期:2015-09-10
  • 通讯作者: 孙书珍。E-mail:ssztml@163.com E-mail:ssztml@163.com
  • 基金资助:
    山东省科技发展计划(2014GGH218009)

Role of CXCL16 in mice with adriamycin induced nephropathy and the protective effects of simvastatin

WANG Cong1, SUN Shuzhen1, ZHEN Junhui2, LI Qian1, XU Yihuai1   

  1. 1. Department of Pediatric Nephrology and Rheumatism and Immunology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Pathology, School of Medicine, Shandong University, Jinan 250012, Shandong, China
  • Received:2014-12-07 Online:2015-09-10 Published:2015-09-10
  • Contact: 孙书珍。E-mail:ssztml@163.com E-mail:ssztml@163.com

PDF (PC)

469

摘要： 目的 观察CXC趋化因子配体16(CXCL16)和氧化低密度脂蛋白(ox-LDL)在阿霉素肾病小鼠中表达的变化及其与肾组织形态学的关系,探讨辛伐他汀对阿霉素肾病肾脏保护作用的机制。方法 将15只雄性Balb/c小鼠分为正常对照组、阿霉素肾病组、辛伐他汀治疗组,每组5只,分别进行相应处理。5周后留取血液、24 h尿液,进行一般生化指标及血清ox-LDL的检测;此后处死小鼠,摘取肾脏组织,采用光镜、电镜和双重免疫荧光技术分别观察肾组织形态结构、超微结构和CXCL16、ox-LDL的表达。结果 与正常对照组相比,阿霉素肾病组与辛伐他汀治疗组小鼠血清总胆固醇和ox-LDL水平升高,肾组织CXCL16、ox-LDL表达增强(P均<0.05)。与阿霉素肾病组相比,辛伐他汀治疗组小鼠肾组织CXCL16、ox-LDL表达均有不同程度的降低(P均<0.05),但血清总胆固醇和ox-LDL水平没有明显下降。相关分析显示,肾组织CXCL16表达水平与肾组织病理学慢性指数、肾组织ox-LDL水平呈明显正相关(rPrP<0.01)。结论 辛伐他汀可能通过抑制肾小球足细胞CXCL16的表达,进而减少足细胞对ox-LDL的摄取而发挥肾脏保护作用。

关键词: 阿霉素, CXC趋化因子配体16, 肾病, 辛伐他汀, 氧化低密度脂蛋白

Abstract: Objective To investigate the roles of chemokine ligand 16 (CXCL16) and oxidized low density lipoprotein (ox-LDL) in mice model with adriamycin induced nephropathy and their relationship with the renal tissue morphology, in order to explore the renal protective effects of simvastatin on adriamycin nephropathy. Methods We divided the mice into the following three groups: control group (n=5), adriamycin nephropathy group (n=5) and simvastatin treated adriamycin nephropathy group (n=5). Each group was treated with corresponding treatment respectively. 5 weeks after injection of adriamycin, the blood and 24 h urine were collected for the detection of general biochemical parameters and serum ox-LDL. After blood and 24 h urine collected, the mice were weighed and sacrificed with kidneys harvested. The renal morphology was observed by light microscopy and transmission electron microscopy, the expressions of CXCL16 and ox-LDL in podocytes were detected by double immunofluorescence techniques. Results Compared with the control group, the levels of TC and ox-LDL in the adriamycin nephropathy and simvastatin treated adriamycin nephropathy were significantly higher (P<0.05), the expressions of CXCL16 and ox-LDL in renal tissue were significantly increased (P<0.05). Compared with the adriamycin nephropathy group, the expressions of renal CXCL16 and ox-LDL in simvastatin treated adriamycin nephropathy group were markedly reduced (P<0.05), but there were no significant differences found in serum TC and ox-LDL between adriamycin nephropathy and simvastatin treated adriamycin nephropathy group. Conclusion Simvastatin has a protective effect on kidney in mice with adriamycin nephropathy. The mechanism might be related to the decreasing expression of CXCL16 in glomerular podocytes, followed by the decreasing endocytosis of ox-LDL in podocytes.

Key words: Nephropathy, Oxidized low density lipoprotein, Adriamycin, Simvastatin, Chemokine ligand 16

中图分类号: 

  • R726.9
[1] Mazzei LJ, García IM, Altamirano L, et al. Rosuvastatin preserves renal structure following unilateral ureteric obstruction in the neonatal rat[J]. Am J Nephrol, 2012, 35(2): 103-113.
[2] de Barros EP, Garcia-Pinto AB, Machado PY, et al. Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs)[J]. J Mol Histol, 2011, 42(4): 323-331.
[3] Liu YZ, Liu M, Zhang YM, Kang L, et al. Protective effects of rosuvastatin in experimental renal failure rats via improved endothelial function[J]. Biol Res Nurs, 2013, 15(3): 356-364.
[4] Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects[J]. Pharmacol Rep, 2007, 59(5): 483-499.
[5] Wantanasiri P, Satirapoj B, Charoenpitakchai M, et al. Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients[J]. Lupus. 2015 Jan 14. pii: 0961203314566634.[Epub ahead of print]
[6] Lydia A, Asanuma K, Nonaka K, et al. Effects of 22-oxa-calcitriol on podocyte injury in adrimycin-induced nephrosis[J]. Am J Nephrol, 2012, 35(1): 58-68.
[7] Saland JM, Pierce CB, Mitsnefes MM, et al. Dyslipidemia in children with chronic kidney disease[J]. Kidney Int, 2010, 78(11): 1154-1163.
[8] Lee HS, Song CY. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis[J]. Am J Nephrol, 2009, 29(3): 62-70.
[9] Zhen J, Li Q, Zhu Y, et al. Increased serum CXCL16 is highly correlated with blood lipids, urine protein and immune reaction in children with active nephrotic syndrome[J]. Diagn Pathol, 2014, 9:23. doi: 10.1186/1746-1596-9-23.
[10] 许艺怀, 孙书珍, 甄军晖, 等. CXCL16和oxLDL在阿霉素肾病小鼠中的变化及意义[J]. 山东大学学报: 医学版, 2014, 52(5): 68-72. XU Yihuai, SUN shuzhen, ZHEN Junhui, et al.Roles of CXCL16 and ox-LDL in mice with adriamycin induced nephropathy[J]. Journal of Shandong University:Health Sciences, 2014, 52(5): 68-72.
[11] Chen G, Lin SC, Chen J, et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis[J]. J Am Soc Nephrol, 2011, 22(10):1876-1886.
[12] Xia Y, Entman ML, Wang Y. Critical role of CXCL16 in hypertensive kidney injury and fibrosis[J]. Hypertension, 2013, 62(6): 1129-1137.
[13] Gutwein P, Abdel-Bakky MS, Schramme A, et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein[J]. Am J Pathol, 2009, 174(6): 2061-2072.
[14] Chen G, Lin SC, Chen J, et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis[J]. J Am Soc Nephrol, 2011, 22(10): 1876-1886.
[15] Wang L, Sun S, Zhou A, et al. oxLDL-induced lipid accumulation in glomerular podocytes: role of IFN-gamma, CXCL16, and ADAM10[J]. Cell Biochem Biophys, 2014, 70(1): 529-538.
[1] 高秀蕊 臧恒昌. 复方烟酸辛伐他汀双层片体外释放度的研究[J]. 山东大学学报(医学版), 2209, 47(6): 109-113.
[2] 杜学识,倪向敏,梁馨予,白倩,朱文艺,王建. 雌马酚对DN的保护作用及潜在靶点[J]. 山东大学学报 (医学版), 2024, 62(8): 49-58.
[3] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[4] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[5] 许琴,高梅,王海民,曹凌瑕,孙成林. 常染色体显性多囊肾病伴原发性醛固酮增多症1例[J]. 山东大学学报 (医学版), 2020, 58(4): 118-120.
[6] 丁华琳,李扬扬,于丰源,战伟伟,于苏国. 达格列净通过Klotho/TGF-β1通路抑制糖尿病肾病大鼠肾纤维化的作用[J]. 山东大学学报 (医学版), 2020, 58(3): 75-80.
[7] 阚娜娜,余丽春,孙书珍,李倩,栾春丽. 儿童肾病综合征型狼疮性肾炎30例临床、病理及近期疗效观察[J]. 山东大学学报 (医学版), 2020, 58(2): 54-59.
[8] 张淑莹,武晓峰,郭丽敏,乔温,彭洁琼,李大庆. 两种阿霉素心力衰竭模型及心功能进展的评估[J]. 山东大学学报 (医学版), 2020, 58(12): 1-7.
[9] 潘艳艳,孙永超,刘雪梅,张洪霞,周蔚然,赵翠芬. 尿液α1-抗胰蛋白酶、尿转铁蛋白水平与小儿原发性肾病综合征激素治疗效果的关联分析[J]. 山东大学学报 (医学版), 2019, 57(12): 74-79.
[10] 冯静静,张鲁伟,赵鹏,郭宁,田军,崔先泉. 彩色多普勒超声在终末期肾病患者自体动静脉内瘘术前评估及术后监测中的应用[J]. 山东大学学报 (医学版), 2018, 56(7): 65-69.
[11] 朱艺馨,范晓慧,陈颜,李凌冰. pH敏感性的聚离子复合物胶束对化疗药物的共递送[J]. 山东大学学报 (医学版), 2018, 56(6): 21-28.
[12] 何鹏娟,颜磊,范明君,刘祥斌,赵兴波. 辛伐他汀对TGF-β诱导的卵巢癌上皮间质转化的影响[J]. 山东大学学报 (医学版), 2018, 56(5): 46-51.
[13] 宋昱,毛洋,刘庆梅,乔磊,帖媛媛,鲁璐,张蕾. 通心络对兔腹主动脉粥样硬化易损斑块中三维应变的影响[J]. 山东大学学报（医学版）, 2017, 55(5): 1-7.
[14] 廉开礼,李炎,张娜,靳桂媛,刘素侠. TIPE3上调P-gp表达降低乳腺癌细胞对阿霉素的敏感性[J]. 山东大学学报（医学版）, 2017, 55(5): 36-42.
[15] 毛文丽,崔美玉,张真真,王尊松,张磊,孔祥雷. 常染色体显性小管间质性肾病1例并文献复习[J]. 山东大学学报（医学版）, 2017, 55(2): 94-96.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发